Close Menu

ImmunoGen

NEW YORK (GenomeWeb) – Roche's Ventana Medical Systems today announced a deal with ImmunoGen to develop an immunohistochemistry-based companion diagnostic test for the oncology therapeutic firm's product candidates.

Myriad, BioMarin Ink Deal to Use HRD Test to ID Responders to PARP Inhibitor

Genomind Introduces Physician Portal for Genecept Results

The US Food and Drug Administration last week approved Roche/Genentech's latest HER2-targeting breast cancer drug, trastuzumab emtansine (T-DM1).

Biotechnology firms participating in the Alzheimer's Disease Neuroimaging Initiative have received plasma and CSF samples from ADNI participants and contributed funds for the processing of roughly 1,000 samples by biomarker discovery firm Rules-Based Medicine.

Peter Williams

Massachusetts Biotechnology Council-BioReady Communities Campaign, Alkermes Relocation, Science + Technology Park at Johns Hopkins, Ohio State University Wright Center of Innovation in Biomedical Imaging, Londonderry Clinical Translational Research and Innovation Centre, Aeras Global TB Vaccine Foundation, BioBusiness Park at Elk Run, Chrysler-University of Delaware, ICON- Qualia Clinical Services

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.